Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Abiraterone in Oligometastatic CRPC (ARTO)
NCT03449719Unknown
- Start
- May 2018
- Primary completion
- Sep 2021
01
Overview
Randomised, open-label trial (2 arms). Primary endpoint: PSA Response Rate at 6 months. Status: unknown.
Beyond the preview
Go deeper on NCT03449719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449719.